MitraClip therapy and surgical edge-to-edge repair in patients with severe left ventricular dysfunction and secondary mitral regurgitation: mid-term results of a single-centre experience
Selected in European Journal of Cardio-Thoracic Surgery by Rylski
De Bonis M, Taramasso M, Lapenna E, Denti P, La Canna G, Buzzatti N, Pappalardo F, Di Giannuario G, Cioni M, Giacomini A, Alfieri O
Eur J Cardiothorac Surg. 2016 Jan;49(1):255-62
LinkRead the abstract
Latest contributionsOutcome after coronary artery bypass grafting and percutaneous coronary intervention in patients with stage 3b-5 chronic kidney disease MitraClip therapy and surgical edge-to-edge repair in patients with severe left ventricular dysfunction and secondary mitral regurgitation: mid-ter... Suprasternal direct aortic approach transcatheter aortic valve replacement avoids sternotomy and thoracotomy: first-in-man experience
The aim of this study was to compare MitraClip therapy with surgical edge-to-edge repair in patients with severe left ventricular dysfunction and secondary mitral regurgitation.
- Single center report on 65 surgical edge-to-edge plus annuloplasty mitral valve repair versus 55 MitraClip patients operated on between 1999 and 2011.
- Age (P = 0.005) and logistic European System for Cardiac Operative Risk Evaluation (P < 0.0001) were significantly higher in the MitraClip group.
- Median follow-up was 4 years.
- Hospital mortality was 3 vs 0% (P = 0.49) in the surgical and MitraClip groups. Survival at 4 years was similar in both groups (P = 0.9).
- The length of hospital stay was 10 days for surgical repair and 5 days for MitraClip (P < 0.0001).
- At 4 years freedom from moderate mitral regurgitation (74.9 ± 5.6% vs 51.4 ± 7.4%, P = 0.01) and freedom from severe mitral regurgitation (92.8 ± 3.4% vs 68.1 ± 7%, P = 0.002) were both significantly higher in the surgical group.
- The use of MitraClip was identified as an independent predictor of recurrence of moderate (HR: 2.1, 95% CI: 1.1–3.9, P = 0.02) as well as of severe MR (HR: 6.1, 95% CI: 1.5–24.3, P = 0.01).
The MitraClip therapy is a safe and effective way to repair secondary MR in selected high-risk patients with relevant comorbidities. The surgical mitral valve repair seems to be more effective at follow-up. This mid-term follow-up study shows similar results in terms of in-hospital mortality and survival in MitraClip and surgical groups. However, since mitral valve after surgical repair remains competent for a longer time when compared with those treated with MitraClip, the future long-term follow-up study may show superiority of the surgical approach.